ProPhase Labs (NASDAQ:PRPH) Stock Passes Above 200-Day Moving Average – Here’s Why

ProPhase Labs, Inc. (NASDAQ:PRPH) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.38 and traded as high as $0.39. ProPhase Labs shares last traded at $0.39, with a volume of 1,125,763 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PRPH shares. Wall Street Zen upgraded ProPhase Labs to a “hold” rating in a research report on Saturday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ProPhase Labs in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

ProPhase Labs Stock Up 10.4%

The company has a market cap of $16.06 million, a P/E ratio of -0.31 and a beta of -0.62. The company has a 50 day moving average of $0.43 and a 200-day moving average of $0.38. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.96 and a quick ratio of 0.93.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The business had revenue of $1.25 million for the quarter, compared to the consensus estimate of $3.55 million. On average, equities analysts predict that ProPhase Labs, Inc. will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds have recently added to or reduced their stakes in PRPH. Cerity Partners LLC bought a new stake in ProPhase Labs during the first quarter worth about $38,000. Citizens Financial Group Inc. RI bought a new stake in ProPhase Labs during the first quarter worth about $109,000. Josh Arnold Investment Consultant LLC bought a new stake in ProPhase Labs during the first quarter worth about $100,000. Sykon Capital LLC bought a new stake in ProPhase Labs during the second quarter worth about $252,000. Finally, XTX Topco Ltd bought a new stake in ProPhase Labs during the second quarter worth about $40,000. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.